Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.
de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S, Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L.
de Rauglaudre B, et al. Among authors: francois e.
Ther Adv Med Oncol. 2022 Dec 26;14:17588359221141307. doi: 10.1177/17588359221141307. eCollection 2022.
Ther Adv Med Oncol. 2022.
PMID: 36601631
Free PMC article.